Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

de Camargo, V. P., Keohan, M. L., D'Adamo, D. R., Antonescu, C. R., Brennan, M. F., Singer, S., Ahn, L. S., Maki, R. G. (May 2010) Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer, 116 (9). pp. 2258-65. ISSN 0008-543X (Print)0008-543X (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/20187095
DOI: 10.1002/cncr.25089

Abstract

BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents. METHODS: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti-inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded. RESULTS: A total of 68 patients received 157 lines of therapy. At the time of last follow-up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow-up was 63 months, and patients received a median of 2 lines of therapy. An intra-abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single-agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression. CONCLUSIONS: Compared with other agents, antiestrogens and anthracycline-containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery.

Item Type: Paper
Uncontrolled Keywords: Adolescent Adult Aged Antineoplastic Agents/*therapeutic use Disease Progression Female Fibromatosis, Aggressive/*drug therapy/mortality/radiography Humans Male Middle Aged Recurrence Treatment Outcome
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 1 May 2010
Date Deposited: 25 Oct 2016 18:49
Last Modified: 25 Oct 2016 18:49
PMCID: PMC2925106
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33707

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving